Psychiatria Danubina · 2025
Evaluation of the macrophage migration inhibitory factor (MIF) -173 G/C variant in bipolar disorder.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mervan Aytac Hasan, Sila Yazar Menekse, Oyaci Yasemin, Pehlivan Sacide
Аннотация
BACKGROUND: This study aimed to study the genetic variant in the MIF -173 G/C in bipolar disorder (BD) by comparing genotype distributions of the MIF -173 G/C variant between patients and healthy controls, considering clinical parameters.
SUBJECTS AND METHODS: A total of 104 patients with BD and 100 healthy volunteers were included in the study. The participants were assessed using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and sociodemographic and clinical data forms. The Young Mania Rating Scale (YMRS), the Hamilton Depression Rating Scale (HAM-D), and The Clinical Global Impression Scale (CGI) were administered to patients with BD. Blood samples were collected from participants to isolate their deoxyribonucleic acid material (DNA). The MIF -173 G/C variant was determined using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis.
RESULTS: The genotype distribution (GG, GC, CC) and allele frequencies (G, C) in the BD group significantly differed from those in the control group. The percentages of the GG genotype (p=.040) and G allele (p=.049) were significantly higher in the BD group compared to the control group. When comparing scale scores and clinical parameters (number of manic episodes, depressive episodes, total episodes, duration of disease, age of onset, and number of hospitalizations) based on MIF genotype distributions in patients with BD, the CGI-I score was significantly higher in the group with the GG genotype compared to the GC/CC group (p = .029).
CONCLUSION: The MIF -173 G/C variant might be associated with BD and treatment response. Additionally, possessing the GG genotype and G allele appears to be disadvantageous in terms of BD diagnosis and treatment resistance in the Turkish population.
SUBJECTS AND METHODS: A total of 104 patients with BD and 100 healthy volunteers were included in the study. The participants were assessed using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) and sociodemographic and clinical data forms. The Young Mania Rating Scale (YMRS), the Hamilton Depression Rating Scale (HAM-D), and The Clinical Global Impression Scale (CGI) were administered to patients with BD. Blood samples were collected from participants to isolate their deoxyribonucleic acid material (DNA). The MIF -173 G/C variant was determined using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) analysis.
RESULTS: The genotype distribution (GG, GC, CC) and allele frequencies (G, C) in the BD group significantly differed from those in the control group. The percentages of the GG genotype (p=.040) and G allele (p=.049) were significantly higher in the BD group compared to the control group. When comparing scale scores and clinical parameters (number of manic episodes, depressive episodes, total episodes, duration of disease, age of onset, and number of hospitalizations) based on MIF genotype distributions in patients with BD, the CGI-I score was significantly higher in the group with the GG genotype compared to the GC/CC group (p = .029).
CONCLUSION: The MIF -173 G/C variant might be associated with BD and treatment response. Additionally, possessing the GG genotype and G allele appears to be disadvantageous in terms of BD diagnosis and treatment resistance in the Turkish population.